Table 2.
Antiviral activity of selected hit compounds against human coronaviruses
| Compound | HCoV-OC43 |
HCoV-229E |
|||
|---|---|---|---|---|---|
| CC50a (μM) | EC50b (μM) | SIc | EC50b (μM) | SIc | |
| 3 | >500 | 14.5 ± 3.5 | >35 | 34.6 ± 8.5 | >15 |
| 4 | 300 ± 18 | 15.8 ± 1.1 | 19 | 23.8 ± 9.9 | 13 |
| 5 | 100 ± 11.9 | 10.6 ± 5.2 | 9 | 10.4 ± 4.1 | 10 |
| 6 | >500 | 4.3 ± 2.6 | >116 | 22.9 ± 4.9 | >22 |
| 25 | >250 | 10.1 ± 5.8 | >25 | >25 | >10 |
| 29 | >250 | 4.8 ± 0.1 | >52 | 15.7 ± 4.8 | >16 |
| RMV | >125 | 0.10 ± 0.04 | >1250 | 0.09 ± 0.03 | >1389 |
Reported values represent the means ± SD of data derived from n ≥ 3 independent experiments in duplicate. Data were obtained by analysis with nonlinear regression function of GraphPad Prism 8.0.
a
Compound concentration that produces 50% of cytotoxicity, as determined by MTT assays at 72 h in MRC-5 cells.
b
50% Effective Concentration at half-maximal response, i.e., the compound concentration that inhibits 50% of plaque formation, as determined by PRA against different CoVs in MRC-5 cells.
c
SI, Selectivity Index (determined as the ratio between CC50 and EC50).